These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 25645203)

  • 1. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
    Katzenwadel A; Wolf P
    Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
    Thelen P; Wuttke W; Seidlová-Wuttke D
    J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategies for targeting the androgen receptor axis in prostate cancer.
    Carver BS
    Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
    Semenas J; Dizeyi N; Persson JL
    Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF-κB signaling promotes castration-resistant prostate cancer initiation and progression.
    Thomas-Jardin SE; Dahl H; Nawas AF; Bautista M; Delk NA
    Pharmacol Ther; 2020 Jul; 211():107538. PubMed ID: 32201312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
    Küronya Z; Bíró K; Gyergyay F; Géczi L
    Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galeterone activity in castration-resistant prostate cancer.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
    [No Abstract]   [Full Text] [Related]  

  • 17. Reconsideration of progression to CRPC during androgen deprivation therapy.
    Mizokami A; Namiki M
    J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.
    Bishop JL; Davies A; Ketola K; Zoubeidi A
    Endocr Relat Cancer; 2015 Jun; 22(3):R165-82. PubMed ID: 25934687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.